Perth medical technology startup Lubdub has enlisted veteran biotech dealmaker Stewart Washer to help it rattle the tin for more cash, with a potential stockmarket float on the horizon after a $6 million fundraising backed by doctors. The company has installed Mr Washer as chair and added pharmaceutical industry heavyweight Sue MacLeman to its board as it prepares for the long and costly business of bringing its heart-monitoring inventions to market. Lubdub doubled its original $3 million fundraising target after winning backing from cardiologists and other medical professionals, but the money will only go so far for a company yet to earn its first dollar. Co-founder Nikhilesh Bappoo said another private capital raising, licensing deals and partnerships with bigger medical technology companies were being considered, along with a possible Australian Securities Exchange listing. “It’s not a cheap process to get a medical device to market, so we’ll be planning a Series A round in the future,” Dr Bappoo said. Mr Washer, who helped float Perth-based $153m Orthocell more than a decade ago, brings a long record of biotech deals, capital raisings and commercialisation to the chairman’s seat. He reckons Australian innovators can hold their own against better-funded overseas rivals. “Our research budgets are so small, but it’s almost like we don’t know better. So we just go and do it,” he said. Ms MacLeman, chair of Medicines Australia and previously head of Lubdub’s advisory board, has joined as a non-executive director. Most of the $6 million will be spent on Electro, a wireless monitor worn on the chest to record the heart’s electrical activity and help doctors identify potentially dangerous irregularities. The device is being tested against conventional heart monitors, with Lubdub aiming to lodge a regulatory submission in 2027. Three other products are in the works. One is a saliva test designed to detect signs of heart damage in about 10 minutes, potentially giving doctors an early indication of trouble while they wait for blood results. Another is a wearable ultrasound patch that could eventually capture images of the heart without a specialist operating a conventional scanner. It remains at proof-of-concept stage. The fourth is a software platform designed to help cardiologists process monitoring data and prepare reports, with artificial intelligence features planned to identify abnormalities faster. Mr Washer sees particular potential for the technology in remote WA communities, where patients can struggle to access specialist heart testing and ongoing care. “Picking these things up early can save a lot of lives, but also save a lot of money for the health system,” he said. Coronary heart disease killed 1755 West Australians last year, making it the State’s second-biggest individual cause of death, according to the Australian Bureau of Statistics. Lubdub remains pre-revenue but has grown from one full-time employee to four full-time equivalent staff, alongside doctoral researchers. It is also chasing government grants to help fund its other products. Dr Bappoo said WA’s emerging medical technology industry was attracting more investors, though accessing the sort of capital routinely available to mining companies remained a challenge. “Being able to unlock the same levels of capital as what goes into the mines at the moment, I think that’s yet to be seen here in WA,” he said. The industry is also grappling with proposed Federal Government changes to research tax concessions that would generally limit cash refunds to companies in their first 10 years, with an extension to 15 years for eligible therapeutic-goods research. “On average, it takes 10 to 15 years to get a biotech to market,” Dr Bappoo said. He said lengthy clinical trials made continued access to the incentives vital for startups facing years of development before earning revenue. For Lubdub, the next hurdle is getting Electro through clinical testing and regulatory approval, while building the investor support needed to finance the rest of its ambitions.
Perth heart-tech startup Lubdub recruits biotech veteran Stewart Washer after oversubscribed $6m raising
Perth heart-tech startup Lubdub has called in veteran biotech dealmaker Stewart Washer and reshuffled its board after raising $6 million from doctors to help bring its first cardiac monitor to market.

